These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 16997718)

  • 1. Virus-like particles: designing an effective AIDS vaccine.
    Young KR; McBurney SP; Karkhanis LU; Ross TM
    Methods; 2006 Sep; 40(1):98-117. PubMed ID: 16997718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Particle-based vaccines for HIV-1 infection.
    Young KR; Ross TM
    Curr Drug Targets Infect Disord; 2003 Jun; 3(2):151-69. PubMed ID: 12769792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined virus-like particle-based polyepitope DNA/protein HIV-1 vaccine design, immunogenicity and toxicity studies.
    Karpenko LI; Ilyichev AA; Eroshkin AM; Lebedev LR; Uzhachenko RV; Nekrasova NA; Plyasunova OA; Belavin PA; Seregin SV; Danilyuk NK; Zaitsev BN; Danilenko ED; Masycheva VI; Bazhan SI
    Vaccine; 2007 May; 25(21):4312-23. PubMed ID: 17418918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virus-like particles as HIV-1 vaccines.
    Doan LX; Li M; Chen C; Yao Q
    Rev Med Virol; 2005; 15(2):75-88. PubMed ID: 15484204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons.
    Chege GK; Thomas R; Shephard EG; Meyers A; Bourn W; Williamson C; Maclean J; Gray CM; Rybicki EP; Williamson AL
    Vaccine; 2009 Jul; 27(35):4857-66. PubMed ID: 19520196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a DNA vaccine expressing a human immunodeficiency virus-like particle.
    Young KR; Smith JM; Ross TM
    Virology; 2004 Oct; 327(2):262-72. PubMed ID: 15351214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AIDS vaccine development: the long and winding road.
    Garber DA; Feinberg MB
    AIDS Rev; 2003; 5(3):131-9. PubMed ID: 14598562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic.
    Guerbois M; Moris A; Combredet C; Najburg V; Ruffié C; Février M; Cayet N; Brandler S; Schwartz O; Tangy F
    Virology; 2009 May; 388(1):191-203. PubMed ID: 19345390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maturation of immune responses to lentivirus infection: implications for AIDS vaccine development.
    Montelaro RC; Cole KS; Hammond SA
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S255-9. PubMed ID: 9814952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetically engineered structure-based vaccine for bluetongue disease.
    Roy P
    Vet Ital; 2004; 40(4):594-600. PubMed ID: 20422594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human immunodeficiency virus-like particles activate multiple types of immune cells.
    Sailaja G; Skountzou I; Quan FS; Compans RW; Kang SM
    Virology; 2007 Jun; 362(2):331-41. PubMed ID: 17276476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants.
    Calarota SA; Weiner DB
    Immunol Rev; 2004 Jun; 199():84-99. PubMed ID: 15233728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines.
    Hammonds J; Chen X; Zhang X; Lee F; Spearman P
    Vaccine; 2007 Nov; 25(47):8036-48. PubMed ID: 17936444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
    McBurney SP; Young KR; Ross TM
    Virology; 2007 Feb; 358(2):334-46. PubMed ID: 17011011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and efficacy of immunodeficiency virus-like particles pseudotyped with the G protein of vesicular stomatitis virus.
    Kuate S; Stahl-Hennig C; Stoiber H; Nchinda G; Floto A; Franz M; Sauermann U; Bredl S; Deml L; Ignatius R; Norley S; Racz P; Tenner-Racz K; Steinman RM; Wagner R; Uberla K
    Virology; 2006 Jul; 351(1):133-44. PubMed ID: 16616946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influenza virosomes as a vaccine adjuvant and carrier system.
    Moser C; Amacker M; Zurbriggen R
    Expert Rev Vaccines; 2011 Apr; 10(4):437-46. PubMed ID: 21506642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
    Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B
    Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge.
    Chung YC; Ho MS; Wu JC; Chen WJ; Huang JH; Chou ST; Hu YC
    Vaccine; 2008 Mar; 26(15):1855-62. PubMed ID: 18329759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virus-like particles: potential veterinary vaccine immunogens.
    Liu F; Ge S; Li L; Wu X; Liu Z; Wang Z
    Res Vet Sci; 2012 Oct; 93(2):553-9. PubMed ID: 22100244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus-like particle vaccines and adjuvants: the HPV paradigm.
    Buonaguro FM; Tornesello ML; Buonaguro L
    Expert Rev Vaccines; 2009 Oct; 8(10):1379-98. PubMed ID: 19803760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.